Intervention

Golimumab

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 21 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting2
Common conditions10
Lead sponsors shown14
Advertisement

Clinical trials

21 shown
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12
RECRUITING
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseNCT03414502 · 2007-12-10
RECRUITING
Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs PlaceboNCT07683026 · 2026-08-08
NOT_YET_RECRUITING
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyNCT05960578 · 2024-05-23
ACTIVE_NOT_RECRUITING
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1DNCT04729296 · 2021-07-01
WITHDRAWN
Effectiveness and Adherence of Golimumab in Rheumatoid ArthritisNCT04188249 · 2019-07-01
UNKNOWN
Golimumab for Adherence in Rheumatoid ArthritisNCT03729349 · 2019-01-15
COMPLETED
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1DNCT03632759 · 2018-08-15
COMPLETED
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationNCT03100253 · 2018-03-01
TERMINATED
A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 DiabetesNCT03298542 · 2017-10-16
COMPLETED
RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid ArthritisNCT03016260 · 2016-12-01
TERMINATED
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 DiabetesNCT02846545 · 2016-08-26
COMPLETED
Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to GolimumabNCT02414984 · 2015-03-01
TERMINATED
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.NCT01295151 · 2011-08-01
COMPLETED
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α BlockersNCT01217814 · 2010-11-01
TERMINATED
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT01248780 · 2010-09-01
COMPLETED
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate TherapyNCT00973479 · 2009-09-01
COMPLETED
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)NCT01362153 · 2007-12-26
COMPLETED
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00361335 · 2006-09-01
COMPLETED
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid ArthritisNCT00207714 · 2003-11-01
COMPLETED
Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young AdultsNCT03945903
NO_LONGER_AVAILABLE

Trial status mix

COMPLETED10
TERMINATED4
RECRUITING2
ACTIVE_NOT_RECRUITING1
NO_LONGER_AVAILABLE1
NOT_YET_RECRUITING1
UNKNOWN1
WITHDRAWN1

Phase mix

PHASE27
PHASE34
PHASE12
PHASE42
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.